Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA's Decline In Promotion Enforcement Highlighted By Celator Booth Letter

Executive Summary

FDA's Office of Prescription Drug Promotion issues only its third letter of 2016, although it hopes to cast wide net by targeting high-profile events like ASCO.

Advertisement

Related Content

FDA's Promotional Reviews Decline, But Says It's Only Part Of Job
FDA Advertising Enforcement Highlighted By HHS Amid Drop In Citations
FDA’s Rx Promo Citations Rise Slightly In 2016; Investigational Drug Promos Scrutinized
‘Who Is The Arbiter?’ US FDA Asks As It Mulls Loosening Off-Label Reins
FDA's Drug Promotion Advisory Reviews Taking Longer
FDA Logo Modernization Aims For Uniform 'Look And Feel'
Off-Label Debate Between FDA, Industry To Formally Begin After Election
Celator Shines At ASCO, Highlights Upside For Jazz
FDA Cites Akorn’s Exhibit Banner At ASHP Clinical Conference

Topics

Related Companies

Related Deals

What to read next

Advertisement
UsernamePublicRestriction

Register

PS119065

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel